Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2021
August 13, 2021 02:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO As is well known, IBT is conducting a large phase III study ("The Connection Study"), the final study in our clinical development program with our drug candidate IBP-9414,...
Infant Bacterial Therapeutics AB utser Marie-Louise Alamaa till ny CFO
July 13, 2021 11:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) tillkännagav idag att Marie-Louise Alamaa har utsetts till Chief Financial Officer (CFO) från och med den 16 augusti 2021. Hon kommer att ingå i företagets...
Infant Bacterial Therapeutics AB appoints Marie-Louise Alamaa as new CFO
July 13, 2021 11:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) today announced that Marie-Louise Alamaa has been appointed Chief Financial Officer (CFO) effective from August 16, 2021. She will be part of the Management...
Infant Bacterial Therapeutics CFO lämnar bolaget
May 20, 2021 10:30 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics ABs Chief Financial Officer (CFO) Daniel Mackey har bestämt sig för att lämna IBT för att anta nya utmaningar. Han kommer att fortsätta i sin nuvarande roll under...
Infant Bacterial Therapeutics CFO leaves the company
May 20, 2021 10:30 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics ABs CFO Daniel Mackey has decided to leave the company to pursue new challenges. He will remain in his current role during his notice period. Michael Owens will be acting...
VDs anförande i samband med Infant Bacterial Therapeutics årsstämma
May 06, 2021 12:50 ET
|
Infant Bacterial Therapeutics AB
Verkställande direktören Staffan Strömbergs anförande i samband med IBTs årsstämma 2021 kan ses här Om Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ) (“IBT”) är ett...
Annual General Meeting of Infant Bacterial Therapeutics CEO speech
May 06, 2021 12:50 ET
|
Infant Bacterial Therapeutics AB
CEO Staffan Strömberg's speech at the Annual General Meeting of IBT is available here. The speech is in Swedish. About Infant Bacterial Therapeutics ABInfant Bacterial Therapeutics AB (publ) is a...
Årsstämma i Infant Bacterial Therapeutics
May 04, 2021 11:00 ET
|
Infant Bacterial Therapeutics AB
På årsstämman i Infant Bacterial Therapeutics AB (publ) den 4 maj 2021 beslutades bland annat följande: fastställande av resultaträkningen och balansräkningen,att ingen utdelning lämnas,beviljad...
Annual General Meeting of Infant Bacterial Therapeutics
May 04, 2021 11:00 ET
|
Infant Bacterial Therapeutics AB
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2021, among other things, the following was resolved: adoption of the annual reportthat no dividend is...
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 31 mars 2021
May 04, 2021 02:00 ET
|
Infant Bacterial Therapeutics AB
VD kommenterar Som bekant genomför vi en fas III-studie (“The Connection Study”) vilket är den sista fasen av vårt kliniska utvecklingsprogram med läkemedelskandidaten IBP-9414 som innehåller...